

Cover Story
By Matthew Bin Han Ong
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- No need for a speculum? A new era of HPV screening
- Most Favored Nation drug pricing could put China on top
- Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line











